Drug intelligence / Profile preview

CP-870,893 + cisplatin + pemetrexed

Development stage: Unknown
Lead developer: Roche
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

CP-870,893 + cisplatin + pemetrexed is a combination therapy consisting of a CD40 agonist monoclonal antibody (CP-870,893) and two chemotherapy agents (cisplatin and pemetrexed). CP-870,893 activates antigen-presenting cells, triggers inflammatory cytokine release, and enhances antitumor cellular immunity. When combined with chemotherapy, it may facilitate tumor antigen release, potentially enhancing the overall antitumor effect.

Targets

CD40 (Cluster of differentiation 40 receptor)

Beyond the preview

Go deeper on CP-870,893 + cisplatin + pemetrexed.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CP-870,893 + cisplatin + pemetrexed.

Explore the full profile